Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Export

@article{citeulike:5927993, abstract = {Therapeutic vaccination of lymphoma patients with tumor-specific immunoglobulin (idiotype, Id) coupled to the carrier protein keyhole limpet hemocyanin (Id-KLH) is undergoing clinical investigation, and methods to improve the immunogenicity of these and other protein tumor antigen vaccines are being sought. Id proteins can be produced via tumor-myeloma hybridomas or recombinant methods in mammalian, bacteria, or insect cells. We now demonstrate that terminal mannose residues, characteristic of recombinant proteins produced in insect cells, yield Id proteins with significantly enhanced immunostimulatory properties compared to Id proteins derived from mammalian cells. Recombinant baculovirus-infected insect cell-derived Id showed higher binding to and activation of human dendritic cells mediated by mannose receptors. In vivo, insect cell-derived Id elicited higher levels of tumor-specific CD8+ cytotoxic T lymphocyte (CTL) and improved eradication of pre-established murine lymphoma. Insect cell and mammalian Id generated similar levels of tumor-specific antibodies, showing no impairment in antibody responses to native tumor antigen despite the glycoslylation differences in the immunogen. Combining insect cell production and maleimide-based KLH conjugation offered the highest levels of anti-tumor immunity. Our data comparing sources of recombinant Id protein tumor antigens used in therapeutic cancer vaccines demonstrate that insect cell-derived antigens can offer several immunologic advantages over proteins derived from mammalian sources.}, author = {Betting, David J. and Mu, Xi Y. and Kafi, Kamran and McDonnel, Desmond and Rosas, Francisco and Gold, Daniel P. and Timmerman, John M.}, citeulike-article-id = {5927993}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.vaccine.2008.10.055}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19000731}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19000731}, day = {7}, doi = {10.1016/j.vaccine.2008.10.055}, issn = {0264-410X}, journal = {Vaccine}, keywords = {glycosylation, nhl}, month = {January}, number = {2}, pages = {250--259}, posted-at = {2009-10-12 17:48:55}, priority = {2}, title = {Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.}, url = {http://dx.doi.org/10.1016/j.vaccine.2008.10.055}, volume = {27}, year = {2009} }

TY - JOUR ID - citeulike:5927993 L3 - citeulike-article-id:5927993 N2 - Therapeutic vaccination of lymphoma patients with tumor-specific immunoglobulin (idiotype, Id) coupled to the carrier protein keyhole limpet hemocyanin (Id-KLH) is undergoing clinical investigation, and methods to improve the immunogenicity of these and other protein tumor antigen vaccines are being sought. Id proteins can be produced via tumor-myeloma hybridomas or recombinant methods in mammalian, bacteria, or insect cells. We now demonstrate that terminal mannose residues, characteristic of recombinant proteins produced in insect cells, yield Id proteins with significantly enhanced immunostimulatory properties compared to Id proteins derived from mammalian cells. Recombinant baculovirus-infected insect cell-derived Id showed higher binding to and activation of human dendritic cells mediated by mannose receptors. In vivo, insect cell-derived Id elicited higher levels of tumor-specific CD8+ cytotoxic T lymphocyte (CTL) and improved eradication of pre-established murine lymphoma. Insect cell and mammalian Id generated similar levels of tumor-specific antibodies, showing no impairment in antibody responses to native tumor antigen despite the glycoslylation differences in the immunogen. Combining insect cell production and maleimide-based KLH conjugation offered the highest levels of anti-tumor immunity. Our data comparing sources of recombinant Id protein tumor antigens used in therapeutic cancer vaccines demonstrate that insect cell-derived antigens can offer several immunologic advantages over proteins derived from mammalian sources. IS - 2 JF - Vaccine SN - 0264-410X EP - 259 TI - Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. VL - 27 SP - 250 KW - glycosylation KW - nhl AU - Betting, David AU - Mu, Xi AU - Kafi, Kamran AU - McDonnel, Desmond AU - Rosas, Francisco AU - Gold, Daniel AU - Timmerman, John PY - 2009/01/07/ UR - http://dx.doi.org/10.1016/j.vaccine.2008.10.055 ER -